Seok Jin Kim, M.D. Ph.D.
Blood Res 2015; 50(4): 187-188Hun Sik Kim, Ph.D.
Blood Res 2015; 50(4): 189-191Maria Shafiq, and Farheen Karim
Blood Res 2015; 50(4): 192Joowon Park
Blood Res 2015; 50(4): 193Bokyung Park, Keon Hee Yoo, and Changsung Kim
Blood Res 2015; 50(4): 194-203Eun-Hye Park, Hyewon Lee, Young-Joo Won, Hee Young Ju, Chang-Mo Oh, Cecile Ingabire, Hyun-Joo Kong, Byung-Kiu Park, Ju Young Yoon, Hyeon-Seok Eom, Eunyoung Lee, and Hyeon Jin Park
Blood Res 2015; 50(4): 204-217Ha-Yon Kim, So-Yeon Lee, Deog-Young Kim, Ji-Young Moon, Yoon-Seok Choi, Ik-Chan Song, Hyo-Jin Lee, Hwan-Jung Yun, Samyong Kim, and Deog-Yeon Jo
Blood Res 2015; 50(4): 218-226Dae-Young Kim, Han-Seung Park, Eun-Ji Choi, Jung-Hee Lee, Je-Hwan Lee, Mijin Jeon, Young-Ah Kang, Young-Shin Lee, Miee Seol, Young-Uk Cho, Seongsoo Jang, Hyun-Sook Chi, Kyoo-Hyung Lee, and Chan-Jeoung Park
Blood Res 2015; 50(4): 227-234Ahmed M. L. Bedewy, Shereen M. EL-Maghraby, Noha S. Kandil, and Waleed R. El-Bendary
Blood Res 2015; 50(4): 235-241Seul Lee, Moon Jin Kim, Jin Seok Kim, Sung Yong Oh, Seok Jin Kim, Yoon Hyung Kwon, In Young Chung, Jung Hun Kang, Deok-Hwan Yang, Hye Jin Kang, Dok Hyun Yoon, Won Seog Kim, Hyo-Jin Kim, and Cheolwon Suh
Blood Res 2015; 50(4): 242-247
Progression-free survival (PFS) and overall survival (OS) curves of patients with intraocular lymphoma. The median PFS of a patient was 19.7 months (95% CI, 8.7-30.7 mo). The estimated 3-year OS of all patients was 75.1%.
|@|~(^,^)~|@|Survival of primary intraocular lymphoma (IOL) patients, including those with primary IOL alone or that simultaneously detected with primary central nervous system lymphoma (PCNSL). Patients with primary IOL that were subsequently diagnosed with PCNSL had a median progression-free survival (PFS) of 25.4 months (95% CI, 18.0-48.3 mo) and a 3-year overall survival (OS) rate of 90%.
|@|~(^,^)~|@|Survival of patients with primary central nervous system lymphoma (PCNSL) that were subsequently diagnosed with intraocular lymphoma (IOL) had a median progression-free survival (PFS) of 12.5 months (95% CI, 6.0-19.0 mo) and a 3-year overall survival (OS) rate of 53.3%.